Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$27.1 million","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Announces Close of US$50 million \/ EUR42 million Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Bio Secures EUR 25 Million Venture Debt Financing from The European Investment Bank","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by ExeVir Bio

    Menu

    ExeVir Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ExeVir Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants

              Details:

              XVR012 is a cocktail of XVR013m and XVR014, targets three distinct epitopes. It is currently being evaluated in preclinical studies for the treatment of Covid-19 infection.

              Lead Product(s): XVR013m,XVR014

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVR012

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 15, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ExeVir Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research

              Details:

              The funding will be used by ExeVir for pre-clinical research towards prophylactic and therapeutic solutions including, XVR021 for dengue by leveraging its unique, modular llama-derived antibody (VHH) technology platform to generate multi-specific antibodies.

              Lead Product(s): XVR021

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVR021

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship

              Deal Size: $1.7 million Upfront Cash: Undisclosed

              Deal Type: Funding June 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ExeVir Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19

              Details:

              XVR013 targets a conserved region in the spike S2 subunit that is essential for viral entry. It neutralizes all previous and current variants of concern and the currently most frequently circulating variants, including XBB, XBB.1.5, BQ.1.1 and BF.7.

              Lead Product(s): XVR013

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVR013

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: VIB

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ExeVir Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ExeVir Bio Secures EUR 25 Million Venture Debt Financing from The European Investment Bank

              Details:

              The EIB financing will help to advance ExeVir’s lead asset, XVR012, into clinical trials for COVID-19. XVR012, is a potent COVID-19 neutralizing antibody that targets the S1 and S2 region of the coronavirus.

              Lead Product(s): XVR012

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVR012

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: European Investment Bank

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing January 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ExeVir Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

              Details:

              Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials.

              Lead Product(s): VHH72-Fc antibody

              Therapeutic Area: Infections and Infectious Diseases Product Name: XVR011

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: VIB

              Deal Size: $50.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing March 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ExeVir Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

              Details:

              Lead asset VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell.

              Lead Product(s): VHH72-FC,Ad26.COV2-S

              Therapeutic Area: Infections and Infectious Diseases Product Name: VHH72-FC

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $27.1 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing May 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY